(Q35072859)

6 August 2017

1 reference

title

Gastrointestinal effects of NSAIDs and coxibs (English)

1 reference

6 August 2017

Loren Laine

1

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Journal of Pain and Symptom Management

6 August 2017

published in

1 reference

6 August 2017

volume

25

1 reference

6 August 2017

issue

2 Suppl

1 reference

6 August 2017

page(s)

S32-40

1 reference

Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Nonsteroidal anti-inflammatory drug gastropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Prophylactic aspirin and risk of peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Salicylsalicylic acid causes less gastroduodenal mucosal damage than enteric-coated aspirin. An endoscopic comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900629-2

7 January 2021

10.1016/S0885-3924(02)00629-2

Identifiers

DOI

1 reference

6 August 2017

1 reference